A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects with Advanced Non-Small Cell Lung Cancer
Study of Study Drug JNJ-61186372 in Patients with Advanced Non-Small Cell Lung Cancer
Sponsor: Janssen Research & Development
Enrolling: Male and Female Patients
IRB Number: AAAS0914
U.S. Govt. ID: NCT02609776
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to see if the study drug, JNJ-61186372, is safe and useful for treating patients with advanced, metastatic, non-small cell lung cancer (NSCLC). There are 2 parts of this study. The first part is to determine the dose of JNJ-61186372 that is safe to give to patients with non-small cell lung cancer. The second part of the study is to gather more information about safety and determine if JNJ-61186372 might be effective for your cancer.
Catherine Shu, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have confirmed unresectable metastatic non-small cell lung cancer? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator